GTHP (Guided Therapeutics) Cyclically Adjusted PS Ratio: (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GTHP Guided Therapeutics Inc GTHP
23 GF Score
Price $0.25
GF Value $1.08
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Guided Therapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Guided Therapeutics  (OTCPK:GTHP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Guided Therapeutics Cyclically Adjusted PS Ratio Related Terms


Guided Therapeutics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Guided Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guided Therapeutics Cyclically Adjusted PS Ratio Chart

Guided Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.01

Guided Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.01 0.00 0.00

GTHP vs PETV, FOFA, CTSO: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Guided Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guided Therapeutics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Guided Therapeutics's Cyclically Adjusted PS Ratio falls into.


GTHP
23GF Score
Guided Therapeutics Inc GTHP
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guided Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Guided Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Guided Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/333.9520*333.9520
=0.000

Current CPI (Jun. 2026) = 333.9520.

Guided Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 241.428 0.000
201612 119.000 241.432 164.602
201703 21.000 243.801 28.765
201706 43.500 244.955 59.304
201709 3.667 246.819 4.962
201712 1.726 246.524 2.338
201803 0.002 249.554 0.003
201806 0.003 251.989 0.004
201809 0.005 252.439 0.007
201812 0.016 251.233 0.021
201903 0.006 254.202 0.008
201906 0.000 256.143 0.000
201909 0.000 256.759 0.000
201912 0.005 256.974 0.006
202003 0.000 258.115 0.000
202006 0.000 257.797 0.000
202009 0.001 260.280 0.001
202012 0.002 260.474 0.003
202103 0.000 264.877 0.000
202106 0.000 271.696 0.000
202109 0.001 274.310 0.001
202112 0.004 278.802 0.005
202203 0.000 287.504 0.000
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.000 301.836 0.000
202306 0.001 305.109 0.001
202309 0.000 307.789 0.000
202312 0.001 306.746 0.001
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.000 319.799 0.000
202506 0.001 322.561 0.001
202509 0.001 324.800 0.001
202512 0.007 324.054 0.007
202603 0.000 330.213 0.000
202606 0.000 333.952 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Guided Therapeutics (GTHP) Overvalued in 2026?

Based on GuruFocus' analysis, Guided Therapeutics stock appears to be undervalued. The current stock price of $0.25 is trading 76.9% below its estimated GF Value™ of $1.08. GuruFocus considers Guided Therapeutics to be Possible Value Trap.

Key valuation signals for GTHP:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $1.08 vs. price of $0.25 (76.9% below fair value)
  • GF Score™: 23/100 with 3 warning signs

No single metric tells the full story. See the GTHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guided Therapeutics Business Description

Address 5835 Peachtree Corners East, Suite B, Peachtree Corners, GA, USA, 30092
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and the extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
23GF Score

Get the complete analysis for GTHP

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$1.08
GF Value